Comparative Pharmacology
Head-to-head clinical analysis: CORTEF ACETATE versus FLUONID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTEF ACETATE versus FLUONID.
CORTEF ACETATE vs FLUONID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressant activity; binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Adult: 5-60 mg orally every 6-12 hours (hydrocortisone base equivalent), or 10-240 mg IV/IM every 12 hours (as hydrocortisone sodium succinate). Dose depends on severity and condition.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
None Documented
None Documented
Plasma terminal half-life is approximately 1.5-2 hours. However, biologic half-life (duration of adrenal suppression) is 18-36 hours due to intracellular receptor binding.
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Primarily renal as inactive metabolites; less than 5% unchanged. Biliary/fecal elimination is minimal (<2%).
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid